Merck has gained this advantage through Keytruda’s approval in first-line non-small cell lung cancer – a lucrative indication where BMS’ drug has failed to produce convincing results.

Designed for lithium-ion batteries in both 2-4 and 3-10 cell series (S), R-BMS F solutions include Renesas’ industry-leading ...

They are much more complex to use than something like a lead acid battery, generally requiring a battery management system (BMS) to keep the cells in tip-top shape. Generally these are standalone ...

The firm reported a 6 percent decrease in Q1 2025 revenues to $11.2 billion compared to $11.87 billion last year.